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Introduction: The EOB is a measure of dyspnea that correlates with CF pulmonary function and exercise tolerance, but has not been shown to track
clinical changes.
Methods: The EOB was administered before and after treatment for twelve episodes of exacerbations in eleven pediatric CF subjects. Each subject
performed the EOB Sustained Phonation and Single Breath Counting measures before and after treatment both at rest and after exercise.
Results: Phonation was signiﬁcantly better pre-exercise after treatment than initially (Z=−2.20, p=0.028). Phonation post-exercise was longer at
follow-up than pre- antibiotics (Z=−1.91, p=0.056). Changes in post-exercise Phonation correlated signiﬁcantly with changes in FEV1 before and
after treatment (R=0.66, p=0.020).
Conclusions: The EOB Sustained Phonation is a validated tool for tracking improvement of pediatric CF patients after antibiotic therapy and has
potential as a research tool to gauge efﬁcacy of new therapies.
© 2012 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Pulmonary exacerbation; Cystic ﬁbrosis; Dyspnea; Exercise-based testing1. Introduction
Pulmonary exacerbations are a major component of the lung
disease of cystic fibrosis (CF). Dyspnea or shortness of breath is
the distressing sensation of breathlessness and is a common clinical
symptom of CF pulmonary exacerbations. However, it is difficult
to quantify, especially in children. Currently, most assessments re-
quire patients to rate their dyspnea via subjective questionnaires
about effects on activity or through patient-reported scales of
“breathlessness” [1–4]. These methods require a relatively high de-
gree of cognitive sophistication and have limited use, especially in
younger children.
Throughout the past decade, attempts have been made to
move from subjective to objective testing of dyspnea in order to
develop a more precise clinical measurement tool [5–10]. A
more objective test could also potentially serve as a useful tool
for research and defining response to treatment.⁎ Corresponding author. Tel.: +1 412 692 5285.
E-mail address: Traci.Kazmerski@chp.edu (T. Kazmerski).
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doi:10.1016/j.jcf.2012.03.005We devised a method to measure dyspnea quantitatively in
young patients called the Ease of Breathing Test (EOB) [11].
The test consists of two measures of dyspnea. The first measure
is based on counting: patients read aloud from a digital stop
watch, counting one number per second as high as possible,
using only one breath. The second is based on the technique
of sustained phonation of the single syllable “ahh.” This test
proved to be a valid and reliable measure of ease of breathing
post-exercise in children with CF [11].
The aim of this study was to provide information on the use
of the EOB as a method to assess the response of acutely ill pe-
diatric patients to a therapeutic intervention. We hypothesized
that the EOB would track the improvement of pediatric patients
with CF as they received antibiotic therapy for a pulmonary
exacerbation.2. Materials and methods
All patients in the Antonio J. and Janet Palumbo Cystic Fi-
brosis Center at Children's Hospital of Pittsburgh of UPMC 6by Elsevier B.V. All rights reserved.
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verity. Inability to complete the EOB was the only exclusion cri-
teria. As the study institution treats patients up to 22 years of age
in the pediatric setting, this was the maximum age recruited. A
need for a population of n=34 was derived from a power calcu-
lation. Limited research personnel available for recruitment
inhibited the study investigators from attaining this in the allotted
recruitment period. Twelve episodes of pulmonary exacerbation
in eleven different patients, four female and seven male, ages
6–21 years old (median age 15.3 years) were studied; the patients
were recruited as they began antibiotic treatment. Recruitment
took place over a period of approximately four months’ time. Pul-
monary exacerbation was defined as an increase in cough or
shortness of breath, unresponsive to standard outpatient therapy,
with severity great enough to justify treatment with IV or oral an-
tibiotics per the patient's cystic fibrosis physician. Treatment
courses lasted between 2 and 6 weeks. In-hospital IV antibiotics
were administered in five episodes and home oral antibiotics
were used in seven episodes.
Each subject performed the two measures (Sustained Phona-
tion and Single Breath Counting) of the EOB both before and
after treatment. Each measure was performed both at rest and
after the three minute Step Test , which requires three minutes
of stepping exercise on a single 15 cm step at a cadence of 30
complete steps per minute (STEP 30) [12].2.1. Sustained phonation
For this measure, subjects wore nose clips and took in a deep
breath and then held the syllable “Ahh” at a normal speaking vol-
ume for as long as possible, using only one breath. The length of
time (in seconds) the subject held the syllable before taking the
next breath served as the sustained phonation score. Subjects per-
formed the maneuver three times at rest and three times after
STEP 30.2.2. Single Breath Counting Score
The Single Breath Counting Score was determined by the sub-
jects' counting aloud in a normal speaking voice, reading the
numbers from a digital stop watch, one number per second. Sub-
jects again wore nose clips and used a normal speaking voice as
they counted as high as possible using one breath after taking in
a big breath. The last number reached before the next breath
served as the score. Subjects performed this maneuver three
times at rest and three times after STEP 30.2.3. VAS
In addition, subjects rated their breathing difficulty by indi-
cating a point on a standard 10 cm Visual Analog Scale (VAS)
between ends identified as “no breathlessness” and “greatest
breathlessness” both before and after treatment. Heart rate, re-
spiratory rate, and oxyhemoglobin saturation were measured at
rest and after STEP 30 as well.2.4. Pulmonary function testing
Pulmonary function testing (PFT) were performed by ATS
standards as a routine part of pulmonary exacerbation treatment
protocol at both initial and follow up visits [13]. Forced expired
volume in one second (FEV1) was used as the representative
PFT value.2.5. Statistical analysis
Data were analyzed using the STATA 9.2 Statistical Analysis
program. All data were treated as pair-wise in nature. All data
were checked for normalcy prior to analysis. Parametric data
were subsequently analyzed via the pair-wise Student's T Test
and nonparametric data were analyzed via Wilcoxon's Signed
Rank Test.2.6. Informed consent
This study was approved by the University of Pittsburgh insti-
tutional review board and consent was obtained from subjects
18 years and older and from parents of younger subjects. Subjects
younger than 18 years of age also gave assent. All subjects were
reimbursed $10 for the initial visit and $40 for follow-up.3. Results
Heart rate (HR) and respiratory rate (RR) were significantly
increased with exercise (p=0.012 HR; p=b0.001 RR). Oxyhe-
moglobin saturation (SaO2) did not change significantly with
exercise or with treatment (p=0.68, p=0.37). Forced expiratory
volume in one second (FEV1) was found to be significantly im-
proved between the initial and follow up visits (p=0.002). The
VAS measurement did not show a significant difference be-
tween the initial and the follow-up visits (p=0.29) (Table 1).
The Sustained Phonation Score significantly shortened after
three minutes of stair-stepping both before (Z=2.51, p=0.012)
and after (Z=2.35, p=0.019) treatment (Fig. 1). The pre-
exercise Sustained Phonation Score was significantly longer
after the course of antibiotics (Z=−2.20, p=0.028). The post-
exercise Sustained Phonation Score was also longer after the
course of antibiotics, but the difference only approached statisti-
cal significance (Z=−1.91, p=0.056) (Fig. 2).
The Single Breath Counting Score decreased after exercise at
both the initial and follow-up visits, but the changes did not
reach statistical significance (Fig. 1). Similarly, the pre- and
post-exercise Single Breath Counting Scores were longer after
treatment, but neither of these changes was statistically significant
(Fig. 2).
Change in FEV1 significantly correlated with change in the
post-exercise Sustained Phonation Score between the initial and
follow-up visits (R=0.66, p=0.020). No significant correlation
was found between the change in FEV1 and the change in the
pre-exercise Sustained Phonation Score or in either the pre- or
post-exercise Single Breath Counting Scores (Fig. 3).
Fig. 2. Effect of treatment on EOB scores. EOB scores compared at rest pre and
post antibiotics and after exercise (STEP30) pre and post antibiotics. P-values
are displayed beneath the X axis and a level of .05 was considered statistically
significant (NS=not significant).
Table 1
Correlation between rest and STEP30 pre and post antibiotics. Data presented
as means (standard deviations). P-values represent pair-wise t-tests performed,
along with their respective confidence intervals. For p-values, a level of .05
was considered statistically significant. Confidence intervals for pair-wise t-
tests are presented in parentheses.
Pre antibiotics Post antibiotics P-value (across visits)
HR (rest) 91.8 (17.8) 82.8 (21.3) .09 [−1.6, 19.8]
HR (STEP30) 115 (27.6) 124 (34.7) .13 [−8.6, 1.3]
P-value
(within visits)
.012
[−39.5, −6.0]
b .001
[−59.9, −22.6]
RR (rest) 18.3 (3.10) 22.0 (7.80) .19 [−2.2, 0.5]
RR (STEP30) 31.3 (10.2) 30.5 (11.0) .27 [−27.5, 8.6]
P-value
(within visits)
b .001
[−18.7, −7.2]
b .001
[−13.9, −3.1]
Sa02 (rest) 97.1 (1.80) 97.8 (1.20) .78 [−5.7, 7.4]
Sa02 (STEP30) 96.8 (2.30) 96.9 (1.80) .37 [−2.3, 0.9]
P-value
(within visits)
.68 [−1.2, 1.7] .25 [−0.7, 2.4]
VAS 3.20 (3.70) 1.80 (3.00) 0.29 [−1.4, 4.2]
FEV1 65.4 (24.4) 82.5 (16.1) 0.002 [−25.6, −7.6]
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We have shown that the Sustained Phonation portion of the
EOB is sensitive to changes in clinical status of children with
CF over the course of antibiotic treatment of a physician-
defined pulmonary exacerbation. The pre-exercise Sustained
Phonation Score was significantly better after the course of an-
tibiotics. When comparing FEV1 and the Sustained PhonationFig. 1. Effect of exercise on EOB scores. EOB scores at rest and after exercise
(STEP30) pre and post antibiotics. P-values are displayed beneath the X axis
and a level of .05 was considered statistically significant (NS=not significant).Score before and after antibiotics, it was found that changes
in the post-exercise phonation significantly correlated with
changes in subjects' pulmonary function.
The other component of the EOB, the Single Breath Count-
ing Score, did not show any significant results. This may be due
to variability in the administration of the counting portion of the
test. Children are more easily able to take small (“cheating”)
breaths while they are counting than during sustained phona-
tion. The ability of the investigator to detect and account for
these breaths may be variable at a given point in time and
could have affected the results of the study. A larger population
and greater experience of personnel administering the EOB
may improve the data from the Single Breath Counting Score.Fig. 3. Change in EOB scores at rest and after exercise (STEP30) compared to
change in FEV1. P-values are displayed next to the R values and a level of .05
was considered statistically significant (NS=not significant).
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cant difference between the initial and the follow-up visits. This
finding further highlights the need for an objective measure of
dyspnea in the pediatric population. It also illustrates that children
are not ideal self-reporters of ease of breathing.
In this relatively small study, eleven subjects were recruited
for a total of twelve episodes of pulmonary exacerbation. The
data were re-analyzed using only the first pulmonary exacerba-
tion EOB data from the duplicate subject, to assure that the sig-
nificance of the study was not affected. No change was seen in
the significance of the results.
The success of the Sustained Phonation portion of the EOB in
this study supports further development of the test as a clinical
tool. Patients who are historically poor reporters of disease sever-
ity or who have PFTs demonstrating reduced effort or poor reli-
ability could benefit from this measure. As it is portable and
easy for patients to perform, it could be adapted into a valid and
reliable means for quickly assessing dyspnea.
Additionally, we feel that the EOB can fill an important void
in the clinical and research armamentarium for evaluating pulmo-
nary exacerbations in children. Currently, to gain Food and Drug
Administration (FDA) approval for a new therapy, there must be
evidence of clinical efficacy. Validating this clinical improve-
ment is challenging in pediatric populations. The CF Foundation
consensus conference on outcome measures for clinical trials in-
cludes a recommendation for exercise-based testing in phase I
and II trials for this population [13]. Some tests have been inves-
tigated in children, but the ideal test has not yet been identified
[14–17]. This lack of an acceptable instrument poses significant
limitations for sponsors and investigators in obtaining approval
of therapies. The EOB may prove the answer to this quandary
as it shows promise as a valid and reliable objective measure of
treatment benefit for CF patients. Furthermore, it is portable, eas-
ily taught, and efficient, making it ideal even in multicenter trials.
The major limitation of this study is population size. A larg-
er sample size would be required to support the current findings
for implementation into clinical practice. A larger study should
be undertaken to improve the power and likely the results of the
study.
In conclusion, the Sustained Phonation portion of the EOB
tracked improvement of pediatric CF patients after antibiotic ther-
apy. With a larger study, the EOB has potential as a clinical tool
to track pulmonary changes and a research tool to gauge efficacy
of new therapies. The development of the EOB as an approved re-
search tool would allow investigators to overcome a major hurdle
in the process of advancing new therapies.References
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